Amylyx prices upsized USD 500.2 million common stock offering at USD 35.5 per share
AMLX•Closing expected in August 2026
Closing is expected on or about Aug. 21, 2026, subject to customary conditions.
Offering priced at $35.5 per share
Amylyx priced an upsized underwritten public offering of 14,090,000 common shares at USD 35.5 each.
Gross proceeds are expected at about USD 500.2 million, before discounts and offering expenses.
Underwriters received a 30-day option to buy up to 2,113,500 additional shares.
Proceeds to fund avexitide and general corporate needs
Net proceeds are earmarked for avexitide pre-commercial work, research and development, working capital, and general corporate purposes.
